(Atlanta, Dec. 11, 2017) -- For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients.
Building on previous research that correlated a longer duration of hospice care with increased quality of end-of-life care, this study analyzed additional factors that have been associated with poorer end-of-life care. These factors included the likelihood of dying in the hospital and the use of chemotherapy in the last two weeks of life, both of which are end-of-life quality measures advocated by the National Quality Forum, a leading voluntary consensus standards-setting organization.
Researchers found that, compared with leukemia patients who did not enroll in hospice care, those who did were far less likely to die in the hospital (3 percent vs 75 percent) or receive chemotherapy during the last two weeks of life (5 percent vs 16 percent). Additionally, they found that patients who needed periodic blood transfusions spent about half as much time in hospice care compared with leukemia patients who were not reliant on these transfusions.
"We found a significant association between transfusion dependence and less meaningful use of hospice care at the end of life among patients with leukemia," said Thomas W. LeBlanc, MD, associate professor of medicine at Duke Cancer Institute in Durham, NC, and senior author of the study. Transfusion-dependent patients were significantly more likely to spend fewer than three days in hospice care (27 percent) compared with patients who were not transfusion-dependent (19 percent), he said, associating longer time spent in hospice care with more meaningful use of the service.
According to Dr. LeBlanc, one of the barriers to the use of hospice care by transfusion-dependent patients with advanced leukemia is that many clinicians consider blood transfusions to be disease-modifying therapy rather than comfort care, as transfusions can help some patients to live longer and feel better. Another is that, under Medicare's reimbursement protocol, the cost of blood transfusions is not compensated separately, but must be covered within the per-diem rate paid for hospice care, reducing the ability of hospice agencies to provide transfusion support as part of their services. Furthermore, the logistical complexities of blood transfusion also often preclude providing the service in patients' homes, where most hospice patients receive care.
"These findings suggest that patients are having to choose between getting the transfusions they need and getting high-quality end-of-life care," Dr. LeBlanc said.
In this study, Dr. LeBlanc, along with Adam J. Olszewski, MD, an assistant professor at Alpert Medical School of Brown University in Providence, RI, and colleagues reviewed data for 21,076 patients with acute or chronic leukemia who died more than 30 days after diagnosis. Patients were considered transfusion-dependent if, within 30 days before death or enrollment in hospice care, they received two or more blood transfusions at least five days apart. Patients' median age was 79.
Results showed that from 2001-2011, slightly more transfusion-dependent patients enrolled in hospice care than patients who were not transfusion-dependent (47 versus 43 percent), but that their median length of stay in hospice care was significantly shorter than those who were not transfusion-dependent (6 versus 11 days).
"This suggests that clinicians tend to enroll patients in hospice during the very last few days of life, but we know from other studies that the earlier patients enter hospice care, the more likely they are to obtain the full benefit of what hospice can offer in terms of an improved quality of life," said Dr. Olszewski, lead study author.
Doctors caring for patients with advanced leukemia who are transfusion-dependent often hesitate to suggest that a patient enter hospice care, said Dr. Olszewski, because doing so usually means having to terminate transfusion support. "Allowing patients to receive transfusion support as part of palliative care could transform the attitude of both patients and clinicians toward hospice care," he added.
"Our findings suggest that allowing reimbursement for palliative transfusions in patients with terminal leukemia would be beneficial for both patients and their families," Dr. LeBlanc said.
Funding for this study was provided by the American Cancer Society and the Cambia Health Foundation.
Adam J. Olzewski, MD, of Brown University, presented the study "Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia " on Saturday, December 9, at 4:00 p.m. EST in Room B302 of the Georgia World Congress Center.
For the complete annual meeting program and abstracts, visit http://www.hematology.org/annual-meeting. Follow @ASH_hematology and #ASH17 on Twitter and like ASH on Facebook for the most up-to-date information about the 2017 ASH Annual Meeting.
The American Society of Hematology (ASH) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The Society publishes Blood®, the most cited peer-reviewed publication in the field, as well as the online, open-access journal, Blood Advances®.
Stephen Fitzmaurice, ASH